View Press Releases
Acroscell Develops CiPA in Silico Modeling to Identify and Optimize Drug Candidates
Acroscell, is a global leading provider of quality services in research and development including cardiac & neuronal safety profiling and translational assays for the academia, pharmaceutical, and biotechnology industries. With a cutting-edge electrophysiological screening platform, Acroscell involves broad drug discovery capabilities, expertise, and proven experience in meeting a wide variety of project objectives successfully with respect to the delivery of quality data and on-time performance. Recently, Acroscell announced the release of its ciPA in silico modeling to support the identification and optimization of drug candidates.
Acroscell offers its clients a full suite of CiPA assessment services. When evaluating candidate drug candidates for cardiotoxicity, many drugs with effects on hERG and QTc prolongation but little actual torsades de pointes (TdP) risk were deprioritized or excluded from further development, or, if once approved, their clinical use would be restricted by inappropriate warning labels in the product.
One of the goals of the CiPA program is to combine data from patch-clamp experiments on a range of important ion channels with computer simulations of the heart's electrical activity. In the second component of the CiPA screening, electrophysiological data generated using an expanded panel of six ion channels was integrated into a computer model of human ventricular action potentials. Creative Bioarray has the ability to support clients in computer modeling through simulations that can help understand client data.
The general advice provided by Creative Bioarray on computer modeling of cardiac electrical activity can lead to a better understanding of the complex nonlinear interactions between different ionic currents and ion concentrations within cells. Additionally, Creative Bioarray implements a range of cellular models available for modeling disease states (e.g. hypertrophic cardiomyopathy, ischemia, long QT syndrome), as well as an ion channel module based on electrophysiological data to plot and interpret results.
Creative Bioarray's CiPA service also provides clients with a robust and cost-effective method to determine cardiac risk, combining cardiac ion channel panel screening (using pharmacological analysis via classical patch clamp electrophysiology) and validated beating iPSC human Cardiomyocyte screening (on a multi-electrode array (MEA) against reference compounds with known clinical outcomes), this service provides a more comprehensive screen than measuring hERG-induced QT prolongation alone.
Creative Bioarray can monitor cellular excitability using microelectrode array (MEA) technology or dual MEA/impedance readouts. Combined with high-fidelity manual patch-clamp electrophysiological data, the plate-based high-throughput output allowed the team to study the effects of compounds on action potentials and membrane currents. Creative Bioarray also has multiple iPSC-derived cardiomyocyte cell lines that have been extensively validated across all phenotypic platforms.
“We can provide project consultation for preclinical research to facilitate your project management and executio, striving with competence and confidence to meet your goals in drug developing with the highest quality.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Our team is flexible, accommodating and respond fast to each of your individual needs.”
As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerate drug development and improve research quality for worldwide projects.